Long-term sertraline treatment of children and adolescents with major depressive disorder

Moira Rynn, Karen Wagner, Craig Donnelly, Paul Ambrosini, Christopher J. Wohlberg, Phyllis Landau, Ruoyong Yang

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective: The aim of this study was to assess the long-term safety, tolerability, and efficacy of sertraline 50-200 mg once-daily in children (6-11 year olds) and adolescents (12-18 year olds) with a Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) diagnosis of major depressive disorder (MDD) Methods: This study consisted of a 24-week open-label observational study of children and adolescents who had completed either of two 10-week double-blind, placebo-controlled trials. The Children's Depression Rating Scale-Revised (CDRS-R) was the primary measure of efficacy. Results: Two hundred ninety nine (299) patients completed the acute studies and were eligible for the extension study. Of these, 226 enrolled, but 5 did not receive treatment. Of 221 patients (107 children and 114 adolescents), 62.4% completed the study. The endpoint mean daily dose was 109.9 mg/day. The mean decrease in CDRS-R score from double-blind baseline was 34.8 points (p < 0.001), with patients showing continued improvement in CDRS-R scores regardless of which treatment they received in the double-blind studies. At endpoint, 86% of patients met CDRS-R responder and 58% CDRS-R remitter criteria. Conclusions: Sertraline appears to be well tolerated and safe over 24 weeks of treatment in children and adolescents with MDD. Children and adolescents treated with sertraline appear to have increased improvement over that seen in the first 10 weeks of treatment. These findings need confirmation in placebo-controlled studies.

Original languageEnglish (US)
Pages (from-to)103-116
Number of pages14
JournalJournal of Child and Adolescent Psychopharmacology
Volume16
Issue number1-2
DOIs
StatePublished - Feb 2006

Fingerprint

Sertraline
Major Depressive Disorder
Depression
Therapeutics
Diagnostic and Statistical Manual of Mental Disorders
Placebos
Double-Blind Method
Observational Studies
Safety

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pediatrics, Perinatology, and Child Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Long-term sertraline treatment of children and adolescents with major depressive disorder. / Rynn, Moira; Wagner, Karen; Donnelly, Craig; Ambrosini, Paul; Wohlberg, Christopher J.; Landau, Phyllis; Yang, Ruoyong.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 16, No. 1-2, 02.2006, p. 103-116.

Research output: Contribution to journalArticle

Rynn, Moira ; Wagner, Karen ; Donnelly, Craig ; Ambrosini, Paul ; Wohlberg, Christopher J. ; Landau, Phyllis ; Yang, Ruoyong. / Long-term sertraline treatment of children and adolescents with major depressive disorder. In: Journal of Child and Adolescent Psychopharmacology. 2006 ; Vol. 16, No. 1-2. pp. 103-116.
@article{e034b25427214f6fbf5655ce0979d95c,
title = "Long-term sertraline treatment of children and adolescents with major depressive disorder",
abstract = "Objective: The aim of this study was to assess the long-term safety, tolerability, and efficacy of sertraline 50-200 mg once-daily in children (6-11 year olds) and adolescents (12-18 year olds) with a Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) diagnosis of major depressive disorder (MDD) Methods: This study consisted of a 24-week open-label observational study of children and adolescents who had completed either of two 10-week double-blind, placebo-controlled trials. The Children's Depression Rating Scale-Revised (CDRS-R) was the primary measure of efficacy. Results: Two hundred ninety nine (299) patients completed the acute studies and were eligible for the extension study. Of these, 226 enrolled, but 5 did not receive treatment. Of 221 patients (107 children and 114 adolescents), 62.4{\%} completed the study. The endpoint mean daily dose was 109.9 mg/day. The mean decrease in CDRS-R score from double-blind baseline was 34.8 points (p < 0.001), with patients showing continued improvement in CDRS-R scores regardless of which treatment they received in the double-blind studies. At endpoint, 86{\%} of patients met CDRS-R responder and 58{\%} CDRS-R remitter criteria. Conclusions: Sertraline appears to be well tolerated and safe over 24 weeks of treatment in children and adolescents with MDD. Children and adolescents treated with sertraline appear to have increased improvement over that seen in the first 10 weeks of treatment. These findings need confirmation in placebo-controlled studies.",
author = "Moira Rynn and Karen Wagner and Craig Donnelly and Paul Ambrosini and Wohlberg, {Christopher J.} and Phyllis Landau and Ruoyong Yang",
year = "2006",
month = "2",
doi = "10.1089/cap.2006.16.103",
language = "English (US)",
volume = "16",
pages = "103--116",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "1-2",

}

TY - JOUR

T1 - Long-term sertraline treatment of children and adolescents with major depressive disorder

AU - Rynn, Moira

AU - Wagner, Karen

AU - Donnelly, Craig

AU - Ambrosini, Paul

AU - Wohlberg, Christopher J.

AU - Landau, Phyllis

AU - Yang, Ruoyong

PY - 2006/2

Y1 - 2006/2

N2 - Objective: The aim of this study was to assess the long-term safety, tolerability, and efficacy of sertraline 50-200 mg once-daily in children (6-11 year olds) and adolescents (12-18 year olds) with a Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) diagnosis of major depressive disorder (MDD) Methods: This study consisted of a 24-week open-label observational study of children and adolescents who had completed either of two 10-week double-blind, placebo-controlled trials. The Children's Depression Rating Scale-Revised (CDRS-R) was the primary measure of efficacy. Results: Two hundred ninety nine (299) patients completed the acute studies and were eligible for the extension study. Of these, 226 enrolled, but 5 did not receive treatment. Of 221 patients (107 children and 114 adolescents), 62.4% completed the study. The endpoint mean daily dose was 109.9 mg/day. The mean decrease in CDRS-R score from double-blind baseline was 34.8 points (p < 0.001), with patients showing continued improvement in CDRS-R scores regardless of which treatment they received in the double-blind studies. At endpoint, 86% of patients met CDRS-R responder and 58% CDRS-R remitter criteria. Conclusions: Sertraline appears to be well tolerated and safe over 24 weeks of treatment in children and adolescents with MDD. Children and adolescents treated with sertraline appear to have increased improvement over that seen in the first 10 weeks of treatment. These findings need confirmation in placebo-controlled studies.

AB - Objective: The aim of this study was to assess the long-term safety, tolerability, and efficacy of sertraline 50-200 mg once-daily in children (6-11 year olds) and adolescents (12-18 year olds) with a Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) diagnosis of major depressive disorder (MDD) Methods: This study consisted of a 24-week open-label observational study of children and adolescents who had completed either of two 10-week double-blind, placebo-controlled trials. The Children's Depression Rating Scale-Revised (CDRS-R) was the primary measure of efficacy. Results: Two hundred ninety nine (299) patients completed the acute studies and were eligible for the extension study. Of these, 226 enrolled, but 5 did not receive treatment. Of 221 patients (107 children and 114 adolescents), 62.4% completed the study. The endpoint mean daily dose was 109.9 mg/day. The mean decrease in CDRS-R score from double-blind baseline was 34.8 points (p < 0.001), with patients showing continued improvement in CDRS-R scores regardless of which treatment they received in the double-blind studies. At endpoint, 86% of patients met CDRS-R responder and 58% CDRS-R remitter criteria. Conclusions: Sertraline appears to be well tolerated and safe over 24 weeks of treatment in children and adolescents with MDD. Children and adolescents treated with sertraline appear to have increased improvement over that seen in the first 10 weeks of treatment. These findings need confirmation in placebo-controlled studies.

UR - http://www.scopus.com/inward/record.url?scp=33645801779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645801779&partnerID=8YFLogxK

U2 - 10.1089/cap.2006.16.103

DO - 10.1089/cap.2006.16.103

M3 - Article

C2 - 16553532

AN - SCOPUS:33645801779

VL - 16

SP - 103

EP - 116

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 1-2

ER -